source
- Will the first approved psychedelic become a blockbuster?Compass and Usona are vying for an FDA first, but pricing, payer coverage and patient access could determine the commercial winner.BioPharma Dive · 32m ago↗ source
- More lawmakers stake out stances on China biotech investmentAhead of a Democrat-led Congress next year, more lawmakers in both parties and chambers are taking fresh positions on whether the US should restrict investments in China’s booming biotech sector. A…Endpoints · 32m ago↗ source
- Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trialLicensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.